An enhanced understanding of the importance of Janus kinase (JAK) and signal transducer
and activator of transcription (STAT) signalling in multiple disease states has led to an …

The current coronavirus pandemic is an ongoing global health crisis due to COVID-19,
caused by severe acute respiratory syndrome coronavirus 2. Although COVID-19 leads to …

Background & Aims Inhibitors of Janus kinases (JAKs) are being developed for treatment of
inflammatory bowel diseases and other immune-mediated diseases. Tofacitinib is effective …

Pouchitis, Crohn's disease of the pouch, cuffitis, polyps, and extraintestinal manifestations of
inflammatory bowel disease are common inflammatory disorders of the ileal pouch. Acute …

Background Knowledge of the real-world effectiveness and safety of tofacitinib for ulcerative
colitis (UC) is relevant to confirm the benefit observed in clinical trials. Methods This …

Background The current COVID‐19 pandemic, caused by SARS‐CoV‐2, has emerged as a
public health emergency. All nations are seriously challenged as the virus spreads rapidly …

Background & Aims Upadacitinib is a novel selective Janus kinase 1 inhibitor that has
shown efficacy in the treatment of moderate to severe ulcerative colitis (UC) and Crohn's …

The two major forms of inflammatory bowel disease (IBD), encompassing Crohn's disease
(CD) and ulcerative colitis (UC), are chronic immune-mediated conditions characterised by …

Background Tofacitinib is a partially selective Janus kinase inhibitor approved for the
treatment of refractory moderate to severe ulcerative colitis [UC]. We sought to define the …

Aim To evaluate the effectiveness and safety of tofacitinib in ulcerative colitis [UC] in real life.
Methods Patients from the prospectively maintained ENEIDA registry and treated with …